Research Unit of Pathology, Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
Department of Pathology, Odense University Hospital, Odense, Denmark.
Breast Cancer. 2020 Jul;27(4):683-695. doi: 10.1007/s12282-020-01066-3. Epub 2020 Feb 27.
To describe relevant pathological parameters of Danish male breast cancer patients (MBCP) diagnosed from 1980 to 2009, and to relate these data to treatment, overall survival (OS) and standardized mortality rate (SMR).
The MBCP cohort was defined from national Danish registers. A total of 643 MBCP were identified with tissue available in 457. Among these, 384 were primary operable. Where tissue blocks were available, tumor type, grade, estrogen receptor (ER), progesteron receptor (PgR) and androgen-receptor (AR) status as well as HER 2 and Ki67 were performed. OS was quantified by Kaplan-Meier estimates and SMR was calculated based on mortality rate among patients relative to the mortality rate in the general population.
Male breast cancer was more often of ductal type, grade II and a very high proportion were ER and AR positive and HER2 negative. Intrinsic subtypes based on immunohistochemical evaluation showed luminal subtype. Ki67 ratio increased over period of study. OS declined by increased age, bigger tumor size, positive lymph node status, higher grade and Luminal B subtype. Hazard ratio and relative risk of SMR were highest for patients aged < 60 years.
Male breast cancer is of luminal subtype, but more often Luminal B. Ki67 is crucial in evaluation of subtypes by immunohistochemistry, but have limitations. Subtyping seems to be of major importance. AR also can have a role in future treatment.
描述丹麦男性乳腺癌患者(MBCP)1980 年至 2009 年的相关病理参数,并将这些数据与治疗、总生存率(OS)和标准化死亡率(SMR)相关联。
MBCP 队列从丹麦国家登记册中确定。共确定了 643 名 MBCP,其中 457 名有组织可利用。在这些患者中,384 名是原发性可手术的。在有组织块可用的地方,进行肿瘤类型、分级、雌激素受体(ER)、孕激素受体(PgR)和雄激素受体(AR)状态以及 HER2 和 Ki67 的检测。OS 通过 Kaplan-Meier 估计进行量化,SMR 是根据患者的死亡率相对于普通人群的死亡率计算得出的。
男性乳腺癌更常见于导管型,分级为 II 级,且非常高比例的患者 ER 和 AR 阳性,HER2 阴性。基于免疫组织化学评估的内在亚型显示为 luminal 亚型。Ki67 比值随着研究时间的推移而增加。OS 随年龄增加、肿瘤体积增大、淋巴结阳性状态、分级升高和 luminal B 亚型而下降。年龄<60 岁的患者的危险比和 SMR 的相对风险最高。
男性乳腺癌是 luminal 亚型,但更常见的是 luminal B。Ki67 在免疫组织化学评估亚型中至关重要,但存在局限性。亚分型似乎非常重要。AR 也可能在未来的治疗中发挥作用。